Cite
HARVARD Citation
Moro-Sibilot, D. et al. (2019). Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Annals of oncology. pp. 1985-1991. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Moro-Sibilot, D. et al. (2019). Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial. Annals of oncology. pp. 1985-1991. [Online].